MEK inhibitors against MET-amplified non-small cell lung cancer

Documenti analoghi

• KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival
  di: Terashima, Masato, et al.
  Pubblicazione: (2014)
• Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
  di: Banno, Eri, et al.
  Pubblicazione: (2016)
• Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
  di: Chiba, Masato, et al.
  Pubblicazione: (2017)
• Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
  di: Togashi, Yosuke, et al.
  Pubblicazione: (2014)
• Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
  di: KOGITA, AKIHIRO, et al.
  Pubblicazione: (2014)